Korro Bio, Inc. has announced a partnership with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration aims to leverage Korro’s proprietary OPERATM platform to enable oligonucleotide-directed RNA edits into two undisclosed targets, with a total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding.